Cited by 5,866Heart Failure Treatment and ManagementClinical practice guidelines implementationCardiovascular Function and Risk Factors

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Open access
Ponikowski, Piotr, Voors, Adriaan A., Anker, Stefan D., Bueno, Héctor, Cleland, John G. F., Coats, Andrew J. S., Falk, Volkmar, González-Juanatey, José Ramón +15 more·2016·European Journal of Heart Failure

Abstract

... Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.592

Cites

657 of 657 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many treatments proven to improve symptoms are infrequently employed because of a neutral or negative effect on disease progression, including diuretics, dobutamine, and morphine.

    “There are in fact many treatments proven to improve symptoms, but they are infrequently employed because of a neutral (or negative) effect on disease progression including diuretics, dobutamine, and morphine. 21”

    From Prioritizing symptom management in the treatment of chronic heart failure (2020) · cites this paper as [21]

    The guidelines say diuretics relieve congestion symptoms (section 7.3), opiates relieve dyspnoea but are not recommended for routine use (Opiates), and inotropes such as dobutamine should be reserved for selected patients because of safety concerns (Vasodilators). They do not support treating all three as infrequently employed because of neutral or negative effects on disease progression: the Diuretics section calls diuretics a cornerstone of acute heart-failure treatment, and section 7.3 reports evidence suggesting reduced death and worsening heart failure. Page numbers are unavailable in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • There are no specific constraints to HF treatment in T2DM patients as recommended by the 2016 ESC guidelines for the management of HF.

    “There are no specific constraints to HF treatment in T2DM patients as recommended by the 2016 ESC guidelines for the management of HF. 116”
  • ACE-inhibitors improve symptoms and reduce morbidity and mortality in patients with HFrEF and T2DM.

    “as they have been shown to improve symptoms and reduce morbidity and mortality.116”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., Rutten, F. H., van der Meer, P., Authors/Task Force Members, & Reviewers, D.
Affiliations
Wroclaw Medical University (PL)
Corresponding author
  • Ponikowski, Piotr
  • Voors, Adriaan A.
Venue
European Journal of Heart Failure
Published
2016-05-20
Volume
18
Issue
8
Pages
891-975
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W4293860347
Cited by
5,866
References
656
Citations by year
2026: 85 · 2025: 205 · 2024: 317 · 2023: 386 · 2022: 601 · 2021: 894 · 2020: 965 · 2019: 881 · 2018: 763 · 2017: 615 · 2016: 145 · 2014: 3
FWCI
659.94
Type
journal article
Language
en
Open access
Locations
  • European Journal of Heart Failure (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • ORBi (University of Liège) (submittedVersion, other-oa)
  • GRO (submittedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion)
Funders
  • American Heart Association
  • American College of Cardiology Foundation
  • National Institute for Health and Care Research (NF-SI-0611-10227)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure, acute heart failure, chronic heart failure, diagnosis, treatment, European Society of Cardiology, risk-benefit assessment
MeSH terms
Acute Disease, Assisted Circulation, Cardiovascular Agents, Chronic Disease, Heart Failure, Heart Function Tests, Humans, Stroke Volume, Heart Transplantation, Cardiac Imaging Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review